DHX vs REGN · rev $141.9M vs P/E 14, rev $14.34B
DHI Group Inc (DHX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
DHI Group Inc (DHX) is a software - application company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported DHX revenue for 2024-12-31 was $141.9M. Net income was $253.0K. Revenue was down 6.6% from 2023-12-31 to 2024-12-31. DHX currently screens at market cap $145.6M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
DHX currently screens at market cap $145.6M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the DHX and REGN stock pages for the full models.
Not investment advice.